Treatment of the dry form of age-related macular degeneration: the studied present and promising future

<p> N.G. Glazko<sup>1,2</sup>, O.A. Kanaeva<sup>2</sup>, M.H. Rabadanova<sup>2</sup> </p> <p> <sup>1</sup>Hospital for War Veterans No. 2, Moscow, Russian Federation </p> <p> <sup>2</sup>Pirogov Russian Nat...

Full description

Saved in:
Bibliographic Details
Main Authors: N.G. Glazko, O.A. Kanaeva, M.H. Rabadanova
Format: Article
Language:Russian
Published: Prime-Media 2022-11-01
Series:РМЖ "Клиническая офтальмология"
Online Access:http://clinopht.com/upload/iblock/9f6/puupdbzoyz3fhy55xfogzucd1juj4gzh.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841526846874714112
author N.G. Glazko
O.A. Kanaeva
M.H. Rabadanova
author_facet N.G. Glazko
O.A. Kanaeva
M.H. Rabadanova
author_sort N.G. Glazko
collection DOAJ
description <p> N.G. Glazko<sup>1,2</sup>, O.A. Kanaeva<sup>2</sup>, M.H. Rabadanova<sup>2</sup> </p> <p> <sup>1</sup>Hospital for War Veterans No. 2, Moscow, Russian Federation </p> <p> <sup>2</sup>Pirogov Russian National Research Medical University, Moscow, Russian Federation </p> <p> Age-related macular degeneration (AMD) is the main cause of central vision loss in elder group of patients. At the same time, annually, the number of people with detected changes in the retina corresponding to different forms of macular dystrophy is steadily growing. The disease is considered to be a highly significant medical, social and economic problem, since a deterioration of the central vision negatively affects the life quality and work capacity of patients. The article presents an analysis of modern views concerning the current therapy possibilities for the dry form of AMD, including the use of nutraceuticals, consisting of lutein, zeaxanthin, mesoseaxanthin, as well as an overview of the directions of development and clinical trials. The use of lutein- and zeaxanthin-containing compounds can be recommended for prevention both the AMD progression and the presence of risk factors for its development, especially in persons over 50 years of age, as well as in the presence of high visual workload. </p> <p> <b>Keywords</b>: age-related macular degeneration, nutraceuticals, carotenoids, lutein, zeaxanthin, mesoseaxanthin. </p> <p> <b>For citation:</b> Glazko N.G., Kanaeva O.A., Rabadanova M.H. Treatment of the dry form of age-related macular degeneration: the studied present and promising future. Russian Journal of Clinical Ophthalmology. 2022;22(4):240–246 (in Russ.). DOI: 10.32364/2311-7729-2022-22-4-240-246. </p>
format Article
id doaj-art-f4f95afe7f124ddbb00f19db72a7c00a
institution Kabale University
issn 2311-7729
2619-1571
language Russian
publishDate 2022-11-01
publisher Prime-Media
record_format Article
series РМЖ "Клиническая офтальмология"
spelling doaj-art-f4f95afe7f124ddbb00f19db72a7c00a2025-01-16T09:39:38ZrusPrime-MediaРМЖ "Клиническая офтальмология"2311-77292619-15712022-11-0122431527Treatment of the dry form of age-related macular degeneration: the studied present and promising futureN.G. Glazko0O.A. Kanaeva1M.H. Rabadanova2Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399<p> N.G. Glazko<sup>1,2</sup>, O.A. Kanaeva<sup>2</sup>, M.H. Rabadanova<sup>2</sup> </p> <p> <sup>1</sup>Hospital for War Veterans No. 2, Moscow, Russian Federation </p> <p> <sup>2</sup>Pirogov Russian National Research Medical University, Moscow, Russian Federation </p> <p> Age-related macular degeneration (AMD) is the main cause of central vision loss in elder group of patients. At the same time, annually, the number of people with detected changes in the retina corresponding to different forms of macular dystrophy is steadily growing. The disease is considered to be a highly significant medical, social and economic problem, since a deterioration of the central vision negatively affects the life quality and work capacity of patients. The article presents an analysis of modern views concerning the current therapy possibilities for the dry form of AMD, including the use of nutraceuticals, consisting of lutein, zeaxanthin, mesoseaxanthin, as well as an overview of the directions of development and clinical trials. The use of lutein- and zeaxanthin-containing compounds can be recommended for prevention both the AMD progression and the presence of risk factors for its development, especially in persons over 50 years of age, as well as in the presence of high visual workload. </p> <p> <b>Keywords</b>: age-related macular degeneration, nutraceuticals, carotenoids, lutein, zeaxanthin, mesoseaxanthin. </p> <p> <b>For citation:</b> Glazko N.G., Kanaeva O.A., Rabadanova M.H. Treatment of the dry form of age-related macular degeneration: the studied present and promising future. Russian Journal of Clinical Ophthalmology. 2022;22(4):240–246 (in Russ.). DOI: 10.32364/2311-7729-2022-22-4-240-246. </p>http://clinopht.com/upload/iblock/9f6/puupdbzoyz3fhy55xfogzucd1juj4gzh.pdf
spellingShingle N.G. Glazko
O.A. Kanaeva
M.H. Rabadanova
Treatment of the dry form of age-related macular degeneration: the studied present and promising future
РМЖ "Клиническая офтальмология"
title Treatment of the dry form of age-related macular degeneration: the studied present and promising future
title_full Treatment of the dry form of age-related macular degeneration: the studied present and promising future
title_fullStr Treatment of the dry form of age-related macular degeneration: the studied present and promising future
title_full_unstemmed Treatment of the dry form of age-related macular degeneration: the studied present and promising future
title_short Treatment of the dry form of age-related macular degeneration: the studied present and promising future
title_sort treatment of the dry form of age related macular degeneration the studied present and promising future
url http://clinopht.com/upload/iblock/9f6/puupdbzoyz3fhy55xfogzucd1juj4gzh.pdf
work_keys_str_mv AT ngglazko treatmentofthedryformofagerelatedmaculardegenerationthestudiedpresentandpromisingfuture
AT oakanaeva treatmentofthedryformofagerelatedmaculardegenerationthestudiedpresentandpromisingfuture
AT mhrabadanova treatmentofthedryformofagerelatedmaculardegenerationthestudiedpresentandpromisingfuture